Activin and Inhibin

[Lys8, Lys9]-Neurotensin (8-13) (JMV438), a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2 , with K i values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors,

[Lys8, Lys9]-Neurotensin (8-13) (JMV438), a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2 , with K i values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors,

[Lys8, Lys9]-Neurotensin (8-13) (JMV438), a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2 , with K i values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors,

[Met5]-Enkephalin, amide TFA is an agonist for δ opioid receptors as well as putative ζ (zeta) opioid receptors.Appearance:SolidIC50&amp: Target:δ and ζ opioid receptorIn Vitro:[Met5]-Enkephalin at 0.1 nM, 10 nM, and 1 μM significantly reduces the

[Met5]-Enkephalin, amide TFA is an agonist for δ opioid receptors as well as putative ζ (zeta) opioid receptors.Appearance:SolidIC50&amp: Target:δ and ζ opioid receptorIn Vitro:[Met5]-Enkephalin at 0.1 nM, 10 nM, and 1 μM significantly reduces the

[Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK 1 receptor selective agonist.In Vitro[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet

[Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK 1 receptor selective agonist.In Vitro[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet

[Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK 1 receptor selective agonist.In Vitro[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet

[Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK 1 receptor selective agonist.In Vitro[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet

A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase , ALK4 and ALK7 , with IC 50 s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5 , ALK4 and ALK7 , respectivelyIn VitroA 83-01 sodium is a potent inhibitor

A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase , ALK4 and ALK7 , with IC 50 s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5 , ALK4 and ALK7 , respectivelyIn VitroA 83-01 sodium is a potent inhibitor

A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase , ALK4 and ALK7 , with IC 50 s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5 , ALK4 and ALK7 , respectivelyIn VitroA 83-01 sodium is a potent inhibitor